Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tango Therapeutics Inc.

8.47
+1.3318.63%
Post-market: 8.630.1600+1.89%18:23 EDT
Volume:3.43M
Turnover:27.93M
Market Cap:942.37M
PE:-6.41
High:8.59
Open:7.25
Low:7.25
Close:7.14
52wk High:8.80
52wk Low:1.03
Shares:111.26M
Float Shares:35.08M
Volume Ratio:1.70
T/O Rate:9.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3218
EPS(LYR):-1.1929
ROE:-76.09%
ROA:-31.74%
PB:6.98
PE(LYR):-7.10

Loading ...

Company Profile

Company Name:
Tango Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
155
Office Location:
201 Brookline Avenue,Suite 901,Boston,Massachusetts,United States
Zip Code:
02215
Fax:
- -
Introduction:
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Alexis Borisy
Director and Chairman of the Board
Barbara Weber
President, Chief Executive Officer and Director
John Ketchum
Director
Kanishka Pothula
Director
Lesley Ann Calhoun
Director
Mace Rothenberg
Director
Malte Peters
Director

Shareholders

Name
Position
Barbara Weber
President, Chief Executive Officer and Director
Daniella Beckman
Chief Financial Officer
Adam Crystal
President of Research and Development